Interventions for toxic epidermal necrolysis

Cochrane Database of Systematic Reviews

Volumn 2002, Issue 4, 2002, Pages

  Majumdar, Samit ^a   Mockenhaupt, Maja ^b   Roujeau, Jean Claude ^c   Townshend, Askari P ^d  

^a Hallamshire Hospital   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HENRI MONDOR HOSPITAL   (France)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORINE; IMMUNOGLOBULIN; PLACEBO; THALIDOMIDE; DERMATOLOGICAL AGENT;

APACHE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL RESEARCH; META ANALYSIS; METHODOLOGY; MORTALITY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; REVIEW; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

DERMATOLOGIC AGENTS; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; RANDOMIZED CONTROLLED TRIALS; THALIDOMIDE;

EID: 3042622225     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001435     Document Type: Review

References (28)

1. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352(9140):1586-9.
2. Assier H. Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Archives of Dermatology 1995;131:540.
3. Bachot N, Revuz J, Roujeau JC. Are intravenous immunoglobulins the treatment of Stevens-Johnson syndrome or toxic epidermal necrolysis?. Allergologie 2001;24:214.
4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Archives of Dermatology 1993;129(1):92-6.
5. Bunger P, Delventhal G. Azathioprinbehandlung bei einem schweren Krankheitsfall von "Lyell Syndrom". Zeitschrift für Haut und Geschlechtskrankheiten 1968;43:853-60.
6. Clarke M, Oxman AD. Optimal search strategy for RCTs. Cochrane Reviewer's Handbook 4.1 [updated June 2000]. Oxford: The Cochrane Collaboration, 2000:appendix 5c.
7. DerSimonian R, Laird N. Meta analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
8. Dolan PA, Flowers FP, Sheretz EF. Toxic epidermal necrolysis. Journal of Emergency Medicine 1989;7(1):65-9.
9. Fine J. Management of acquired bullous skin diseases. New England Journal of Medicine 1995;133:1475-84.
10. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn centre survival of patients with toxic epidermal necrolysis managed without corticosteroids. Annals of Surgery 1986;204:503-12.
11. Hedges LV, Olkin I. Statistical methods for meta-analysis. New York: Academic Press, 1985.
12. Heimbach DM, Engrav LH, Marvin JA, Harnar TA, Grube BJ. Toxic epidermal necrolysis: a step forward in treatment. Journal of the American Medical Association 1987;257:2171-5.
13. Heng MYC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis: clinical and pathophysiological aspects. Journal of the American Academy of Dermatology 1991;25:778-86.
14. Kelly JP, Auquier A, Rzany B, Naldi L, Bastuji-Garin S, et al. An international collaborative case control study of severe cutaneous adverse reactions (SCAR). Journal of Clinical Epidemiology 1995;48(9):1099-8.
15. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. British Journal of Dermatology 1956;68:355-61.
16. Mockenhaupt M, Schopf E. Epidemiology of drug induced severe skin reactions. Seminar in Cutaneous Medicine & Surgery 1996;15(4):236-43.
17. Mockenhaupt M, Schröder W, Schlingmann J, Schneck B, Hering O, Schöpf E. Clinical re-evaluation of erythema exsudativum multiforme majus and Stevens-Johnson syndrome resulting in a different etiology. The Journal of Investigative Dermatology 1999;112:661.
18. Pruitt BA. Burn treatment for the unburned. Journal of the American Medical Association 1987;257:2207-8.
19. Renfro L, Grant-Kels JM, Daman LA. Drug induced toxic epidermal necrolysis treated with cyclosporin. International Journal of Dermatology 1989;28:441-4.
20. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, et al. Toxic epidermal necrolysis: clinical finding and prognosis factors in 87 patients. Archives of Dermatology 1987;123:1160-65.
21. Revuz J, Roujeau JC. Advances in toxic epidermal necrolysis. Seminar in Cutaneous Medicine & Surgery 1996;15(4):258-66.
22. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. New England Journal of Medicine 1990;333:1600-7.
23. Sakellariou G, Koukoudis P, Karpouzas J, Alexopoulos E, Papadopoulou D, Chrisomalis F, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). International Journal of Artificial Organs 1991;14(10):634-8.
24. Schulz KF, Chalmers I, Haynes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408-12.
25. Stables GI, Lever RS. Toxic epidermal necrolysis and systemic corticosteroids. British Journal of Dermatology 1993;128:357-60.
26. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
27. Villada G, Roujeau JC, Cordonnier C, Bagot M, Keuntz M, Wechsler J, et al. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. Journal of the American Academy of Dermatology 1990;23:870-5.
28. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Statistics in Medicine 1991;10:1665-77.